Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.
Michael L WangWojciech JurczakMats JerkemanJudith TrotmanPier L ZinzaniDavid BeladaCarola BoccominiIan W FlinnPratyush GiriAndre GoyPaul A HamlinOlivier HermineJosé-Ángel Hernández-RivasXiaonan HongSeok Jin KimDavid LewisYuko MishimaMuhit ÖzcanGuilherme F PeriniChristopher PocockYuqin SongStephen E SpurgeonJohn M StorringJan WalewskiJun ZhuRui QinTodd HenningerSanjay DeshpandeAngela HowesSteven Le GouillMartin Dreylingnull nullPublished in: The New England journal of medicine (2022)
Ibrutinib treatment in combination with standard chemoimmunotherapy significantly prolonged progression-free survival. The safety profile of the combined therapy was consistent with the known profiles of the individual drugs. (Funded by Janssen Research and Development and Pharmacyclics; SHINE ClinicalTrials.gov number, NCT01776840.).